CardioKine Inc. is a specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications.

We both in-license and develop innovative new compounds and therapies to address what is a growing epidemic around the industrialized world. In the U.S. alone there are five million heart failure patients with over one million hospitalizations and 550,000 new cases each year. It is estimated that heart failure accounts for three billion dollars in pharmaceutical costs and $30 billion in total healthcare costs annually.

Cardiokine raised $37MM in March 2004 in a Series A private equity financing led by Perseus-Soros Biopharmaceutical Fund, L.P. and HealthCare Ventures VII, L.P. Also participating in the financing were Care Capital Investments II, L.P., CIBC WMC Inc., and Burrill Life Sciences Capital Fund, L.P. An additional $50MM was raised in April 2006 in a Series B private equity round led by Advent Venture Partners and Fidelity Biosciences Group. Also participating in the second round were Teachers Private Capital, Perseus-Soros Biopharmaceutical Fund, Health Ventures VII, LP, Care Capital Investments II, LP, CIBC World Markets, Inc. and Burrill Life Sciences Capital Fund.